Parmax Pharma Ltd Board Approves FY26 Financial Results

Parmax Pharma Ltd announced that its Board of Directors met on June 3, 2026, to approve the company's standalone financial results for the quarter and financial year ended March 31, 2026. The audited results, along with the auditors' reports and a declaration of unmodified opinion from the Managing Director, were submitted as per SEBI regulations. The board meeting commenced at 6:01 PM IST and concluded at 6:30 PM IST. The filing also highlighted key audit matters identified by the independent auditors, including an unverified insurance claim, potential contravention of Section 187(1) of the Companies Act regarding investments, non-provision of depreciation on certain plants, and non-compliance with Ind AS 19 for employee benefits.